Drug Profile
Research programme: biodefence antibodies - Diversa
Alternative Names: Biodefense antibodies - DiversaLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Diversa
- Class Antibodies; Antibody diagnostics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax; Yersinia infections
Most Recent Events
- 06 Jan 2009 Discontinued - Preclinical for Anthrax in USA (Parenteral)
- 15 Aug 2003 Preclinical trials in Anthrax in USA (Parenteral)
- 15 Aug 2003 Preclinical trials in Yersinia infections in USA (Parenteral)